Helus Pharma Inc. (HELP) shareholders
HELPNasdaqPharmaceutical PreparationsFiscal year ends March 31
$9.39+0.32 (+3.53%)
Close on Nov 11, 2026Market cap $484.82MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
57.9%
30M of 52M shares
Institutional holders
100
29 new, 9 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
9 buys · 0 sales
Net bought $9.67M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (9.90%), Point72 Capital Advisors, Inc. (9.90%) | 6,410,778 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| VHCP Management III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 5,111,412 | 9.90% | 13G (passive) | Oct 31, 2025 |
| So Eric H. L. | 4,423,894 | 5.80% | 13D (active) | Sep 1, 2026 |
| Glavine Paul | 4,407,456 | 5.80% | 13D (active) | Sep 1, 2026 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (5.29%), Phillip Gross (5.29%) | 3,289,250 | 5.29% | 13G (passive) | Jun 30, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (6.09%), David Kroin (6.09%) | 3,072,250 | 6.09% | 13G (passive) | Oct 28, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.70%), Millennium Group Management LLC (5.70%) and 1 more | 2,829,893 | 5.70% | 13G (passive) amendment | Apr 17, 2026 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (9.10%), Tang Capital Partners, LP (6.20%) | 1,830,097 | 9.10% | 13G (passive) amendment | Mar 31, 2025 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (6.30%), Steven A. Cohen (6.30%) | 1,326,185 | 6.30% | 13G (passive) | May 20, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HELP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| VR Adviser, LLC | 3,851,654 | 7.46% | $25.46M | – | 0.77% |
| Orbimed Advisors LLC | 3,271,400 | 6.34% | $21.62M | −561,443 | 0.40% |
| Adage Capital Partners Gp, L.L.C. | 3,060,000 | 5.93% | $20.23M | +2,360,000 | 0.03% |
| Millennium Management LLC | 2,632,156 | 5.10% | $17.40M | +216,315 | 0.01% |
| Rosalind Advisors, Inc. | 1,956,814 | 3.79% | $12.93M | +425,000 | 4.80% |
| Sphera Funds Management Ltd. | 1,620,753 | 3.14% | $10.71M | +633,663 | 1.40% |
| Acorn Capital Advisors, LLC | 1,540,266 | 2.98% | $10.18M | – | 2.78% |
| DCF Advisers, LLC | 1,434,988 | 2.78% | $9.49M | +743,000 | 1.68% |
| Sio Capital Management, LLC | 1,300,000 | 2.52% | $8.59M | New | 1.42% |
| Nan Fung Group Holdings Ltd | 987,222 | 1.91% | $6.53M | +527,222 | 4.96% |
| Boxer Capital Management, LLC | 790,000 | 1.53% | $5.22M | +150,000 | 0.39% |
| Logos Global Management LP | 750,000 | 1.45% | $4.96M | New | 0.21% |
| Citadel Advisors LLC | 620,959 | 1.20% | $4.10M | −256,388 | 0.00% |
| DAFNA Capital Management LLC | 514,061 | 1.00% | $3.40M | +15,700 | 0.65% |
| Walleye Capital LLC | 502,554 | 0.97% | $3.32M | New | 0.01% |
| Morgan Stanley | 461,886 | 0.89% | $3.05M | −563,432 | 0.00% |
| Knott David M Jr | 370,000 | 0.72% | $2.45M | +20,000 | 1.29% |
| Bank Of America Corp /De/ | 337,435 | 0.65% | $2.23M | New | 0.00% |
| AdvisorShares Investments LLC | 292,711 | 0.57% | $1.93M | +97,107 | 0.23% |
| Jane Street Group, LLC | 280,903 | 0.54% | $1.86M | +174,554 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 100 | 30M | 57.9% | 29 / 29 | 14 / 9 | 10M | 4M |
| Q1 2026 | 81 | 24M | 46.7% | 17 / 15 | 20 / 15 | 3M | 9M |
| Q4 2025 | 80 | 30M | 58.8% | 23 / 20 | 14 / 17 | 24M | 3M |
| Q3 2025 | 74 | 9M | 18.0% | 23 / 17 | 6 / 5 | 2M | 1M |
| Q2 2025 | 56 | 8M | 16.1% | 7 / 11 | 9 / 7 | 1M | 1M |
| Q1 2025 | 56 | 8M | 15.2% | 13 / 18 | 3 / 9 | 1M | 0M |
| Q4 2024 | 53 | 7M | 13.4% | 19 / 9 | 6 / 9 | 4M | 3M |
| Q3 2024 | 45 | 6M | 12.0% | 45 / 0 | 0 / 0 | 6M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Glavine | Chief Growth Officer, Director | 4,981,132 | 9.65% | Oct 1, 2026 |
| Greg Cavers | Chief Financial Officer | 128,937 | 0.25% | Oct 1, 2026 |
| Michael Halstead | Chief Executive Officer | 168,568 | 0.33% | Sep 21, 2026 |
| Suresh K. Durgam | Director | – | – | Nov 2, 2026 |
| Freda C. Lewis-Hall | Director | 100,000 | 0.19% | Oct 26, 2026 |
| Amir Inamdar | Director | 227,822 | 0.44% | Oct 26, 2026 |
| Mark Lawson | Director | 160,026 | 0.31% | Oct 23, 2026 |
| Grant Froese | Director | 161,263 | 0.31% | Oct 23, 2026 |
| Eric Hoskins | Director | 158,632 | 0.31% | Oct 23, 2026 |
| Theresa Firestone | Director | 76,879 | 0.15% | Oct 23, 2026 |
| Eric H. L. So | Director | 4,766,630 | 9.23% | Oct 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric H. L. So Director | Sep 30, 2026 | Award | +248,000 | – | – | 4,713,014 |
| Paul Glavine Chief Growth Officer, Director | Sep 30, 2026 | Award | +248,000 | – | – | 4,750,191 |
| Greg Cavers Chief Financial Officer | Sep 29, 2026 | Buy | +3,000 | $12.91 | $38.73K | 3,000 |
| Michael Halstead Chief Executive Officer | Sep 21, 2026 | Buy | +100,000 | $13.47 | $1.35M | 168,568 |
| Eric H. L. So Executive Chair, Director | Sep 8, 2026 | Buy | +100,000 | $12.39 | $1.24M | 4,465,014 |
| Paul Glavine Chief Growth Officer | Sep 8, 2026 | Buy | +100,000 | $12.47 | $1.25M | 4,271,252 |
| Paul Glavine Chief Growth Officer | Sep 8, 2026 | Buy | +100,000 | $12.47 | $1.25M | 4,271,252 |
| Eric H. L. So Executive Chair, Director | Sep 4, 2026 | Buy | +100,000 | $12.09 | $1.21M | 4,365,014 |
| Paul Glavine Chief Growth Officer | Sep 3, 2026 | Buy | +100,000 | $11.78 | $1.18M | 4,171,252 |
| Eric H. L. So Executive Chair, Director | Sep 1, 2026 | Buy | +95,000 | $11.81 | $1.12M | 4,265,014 |
| Paul Glavine Chief Growth Officer | Aug 31, 2026 | Buy | +90,000 | $11.59 | $1.04M | 4,071,252 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
3M shares short
Days to cover
2.0
At 1M shares a day
Change since last report
-11.5%
From 3M shares
Short volume, 20 days
39.2%
Of volume reported to FINRA
Shares sold short, last 10 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Helus Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 60,516 shares on Oct 2, 2026 over the last 90 days.
See a number that looks wrong?